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De tudo na vida 
ficaram três coisas: 
A certeza de que estamos sempre começando... 
A certeza de que precisamos continuar... 
A certeza de que seremos interrompidos antes de terminar... 
 
Portanto, devemos: 
Fazer da interrupção um caminho novo... 
Da queda, um passo de dança... 
Do medo, uma escada... 
Do sonho, uma ponte... 
 
Fernando Pessoa 
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CONSIDERAÇÕES INICIAIS 
CONSIDERAÇÕES INICIAIS 
O termo Síndrome Metabólica (SM) consiste em um conjunto de 
fatores de risco cardiovasculares. Por muito tempo a doença cardiovascular 
(DCV) foi considerada a maior causa de morbimortalidade em paises do 1º 
mundo (1). Durante esse período houve preocupação em identificar os fatores que 
contribuíam para isso. 
Embora essas anormalidades metabólicas tenham sido 
reconhecidas antes de 1923 (2), somente em 1988 Reaven (3) definiu a Síndrome 
X, caracterizada pela presença de resistência a insulina, hiperglicemia, 
hipertensão, diminuição de HDL e aumento de triglicérides. Reaven e cols não 
incluíram a obesidade abdominal, mas atualmente ela é reconhecida como um 
componente essencial da síndrome. Os autores postularam que a resistência à 
insulina e a hiperinsulinemia compensatória predispõe os pacientes a hipertensão 
arterial, dislipidemia e Diabetes Mellitus tipo 2 (DM2), resultando em alta 
incidência de doença cardiovascular (4,5). 
A resistência à insulina foi considerada a alteração metabólica 
primária e todas as demais seriam dela decorrentes. Posteriormente, o próprio 
autor, em outros trabalhos, ampliou o conceito de síndrome, sugerindo então a 
inclusão de outras manifestações clínicas, como a hiperuricemia, aumento dos 
níveis de PAI-1 e a obesidade abdominal (6). O reconhecimento desse conjunto de 
alterações metabólicas foi ao longo do tempo recebendo inúmeras denominações, 
como Síndrome de Reaven, quarteto mortal, Síndrome da resistência a insulina, 
Síndrome da obesidade-dislipidemia ou Síndrome Plurimetabólica, para chegar 
finalmente a ser denominada Síndrome Metabólica pela Organização Mundial da 
Saúde.  
Os componentes da síndrome têm sido reconhecidos como fatores 
de risco cardiovasculares. Portanto é compreensível que a própria síndrome 
constitua por si mesma um fator de risco cardiovascular muito importante. No 
contexto da SM, ainda não estão totalmente esclarecidos todos os caminhos 
metabólicos que associam resistência à insulina e seus demais elementos às 
complicações inerentes, porém evidências tornam-se mais claras a exemplo do 
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papel da obesidade central nas doenças cardiovasculares que desponta 
atualmente como elemento diagnóstico (6).  
Devido ao grande risco de morbidade e mortalidade cardiovascular 
associado com a SM, é importante identificarmos quais pacientes são de risco. No 
entanto a identificação de pacientes com a síndrome é dificultada pela ausência 
de consenso na sua definição e nos pontos de cortes de seus componentes. 
 A WHO (World Health Organization) definiu SM em 1988 (7) e tem 
como ponto de partida a avaliação da resistência à insulina ou do distúrbio do 
metabolismo da glicose, o que dificulta a sua utilização. Mais recentemente o ATP 
III-NCEP (8) definiu SM pela presença de três ou mais critérios que se seguem: 
Hipertensão Arterial (PA ≥ 130/85), circunferência da cintura > 102 cm para 
homens e > 88 cm para mulheres, valores de Triglicérides plasmáticos > 150 
mg/dl, valores de HDL-Colesterol < 40 mg/dl em homens e < 50 mg/dl em 
mulheres, valores de Glicemia > 100 mg/dl. Os critérios utilizados pelo NCEP 
foram propostos para tornar mais fácil a identificação de pacientes com SM na 
prática clínica (9). 
Em 2005, a Federação Internacional de Diabetes (IDF) definiu 
SM (10) pela presença de cintura abdominal ≥ 94 cm em homens e ≥ 80 cm em 
mulheres, mais a presença de 2 ou mais fatores: Hipertensão Arterial (PA ≥ 
130/85 mmHg), valores de triglicérides plasmáticos ≥ 150 mg/dl, valores de HDL 
colesterol < 40 mg/dl em homens e < 50 mg/dl em mulheres, valores de glicemia > 
100mg/dl. Devido a grande associação de obesidade abdominal e SM, o 
consenso proposto pelo IDF identifica a cintura abdominal como um componente 
essencial para o diagnóstico de SM. Atualmente estima-se que a prevalência de 
SM seja de 6,7% em indivíduos de 20-29 anos e 43,5% naqueles entre 60-69 
anos (1).  
Independente do critério usado sabe-se que o diagnóstico de SM 
aumenta o risco de DCV (11). Pacientes com SM têm incremento de 2 vezes na 
mortalidade e incidência 3 vezes maior de doença cardiovascular ou AVC do que 
pessoas sem SM (5). Além disso, pacientes com SM têm risco 5 vezes maior de 
desenvolver DM2 (12). Por isso, a importância de se identificar SM precocemente é 
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fundamental para promover intervenções no estilo de vida e tratar precocemente 
pacientes com SM, evitando assim DCV. 
Neste contexto, o presente estudo analisou a associação entre a 
ocorrência da SM, definida pelos dois critérios, e a ocorrência de doença 
cardiovascular estabelecida, em uma população de indivíduos com pelo menos 1 
componente da SM sobre o risco cardiovascular. A interação entre a ocorrência 
de DCV e a SM foi estudada em função da presença ou não de DM nesta 
população. 
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ABSTRACT 
We evaluated the significance of a diagnosis of metabolic syndrome (MetS), as 
defined by the National Cholesterol Education Program (NCEP) and by the 
International Diabetes Federation (IDF), in the evaluation of cardiovascular risk in 
hypertensive patients. The patients were evaluated to identify MetS and any history 
of cardiovascular disease (CVD). This was a cross-sectional study involving 638 
patients, of which 202 (31.7%) had diabetes. The prevalence of MetS was 54.7% 
when the IDF criteria were used, compared with 45.5% when the NCEP criteria 
were used (p < 0.05). Using either set of criteria, MetS was associated with type 2 
diabetes mellitus (T2DM) (NCEP,OR: 6.8; 95% CI: 4.7-10 and IDF, OR: 8.4; 95% 
CI: 5.4-13; p < 0.05 for both). We found that, regardless of the diagnostic criteria 
used, MetS correlated significantly with the risk and history of CVD (NCEP, OR: 
2.04; 95% CI: 1.2-3.4; p < 0.05; and IDF, OR: 2.68; 95% CI: 1.5-4.8; p < 0.05), 
partially caused by the inclusion of patients with diabetes in the sample. In patients 
without diabetes, MetS diagnosed using the IDF criteria alone was associated with a 
history of CVD (OR: 2.4; 95% CI: 1.1-5.2; p = 0.029 vs. NCEP criteria, OR: 1.99; 
95% CI: 0.9-4.3, p = NS). In patients with T2DM, MetS was not associated with 
CVD, regardless of the criteria used. We conclude that, among individuals without 
diabetes, an IDF criteria-based diagnosis of MetS is useful in identifying those at 
greater risk for cardiovascular disease. Among patients with diabetes, a diagnosis of 
MetS, regardless of the criteria used, is of little utility in assessing cardiovascular 
risk. However, a diagnosis of MetS, using either set of criteria, is useful for 
identifying individuals more likely to develop T2DM. 
 
Keywords:  
Metabolic Syndrome; Cardiovascular Disease, Cardiovascular Risk Factors. 
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INTRODUCTION 
Cardiovascular disease (CVD) is the principal cause of death in 
various populations, being responsible for 37.7% of all deaths in the American 
population (1). Various risk factors for CVD have been identified, among which are 
smoking, type 2 diabetes mellitus (T2DM), systemic arterial hypertension, 
dyslipidemia and visceral obesity (2). There has been a consistent increase in the 
prevalence of visceral obesity, which has attenuated the increase in life 
expectancy. According to the World Health Organization (WHO), the number of 
overweight and obese individuals worldwide will reach 1.5 billion by 2015 (1).  
Visceral obesity is intimately linked to metabolic syndrome (MetS), 
which is a disorder involving cardiovascular risk factors that are typically 
associated with insulin resistance (3). Various studies have demonstrated that 
MetS correlates with an increase in the number of cardiovascular events and in 
the occurrence of T2DM (4-6). The 2006 prevalence of MetS was estimated to 
range from 6.7% (in the 20-29 age bracket) to 43% (in the 60-69 age bracket) (1).  
Due to the high cardiovascular morbidity and mortality associated 
with MetS (6-18), the appropriate characterization of the syndrome is extremely 
relevant. Among individuals with MetS, the mortality rate is twice as high as in 
those without. In addition, the incidence of CVD and cerebral vascular accident is 
three-times higher in individuals without MetS than in those without (5). 
Furthermore, the risk of developing T2DM is five-times greater among patients 
with MetS than among those without (19). However, the lack of a universal standard 
for MetS criteria hinders understanding of the magnitude of its impact on the 
occurrence of these events. The definition of MetS proposed by the WHO (20) was 
based on clinical and laboratory data that would indicate insulin resistance, 
thereby making it difficult to apply in clinical practice. In 2001, the National 
Cholesterol Education Program (NCEP) Adult Treatment Panel III (ATP III) 
proposed a new definition (21), which considered the following components: blood 
glucose; blood pressure; serum levels of high-density lipoprotein (HDL) cholesterol 
and triglycerides; and waist circumference. Although the NCEP ATP III criteria are 
easier to apply, evidence suggests that cardiovascular risk is increased at blood 
glucose and waist circumference values lower than those initially 
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recommended (22,23). Therefore, in 2005, the International Diabetes Federation 
(IDF) reformulated the criteria for the classification of MetS and designated waist 
circumference as an essential component of the definition, as well as establishing 
specific cut-off points for individuals of various ethnicities (24). 
The aim of the present study was to analyze the association between 
a diagnoses of MetS, defined using either set of criteria, and the presence of an 
established CVD, in a population of individuals presenting hypertension. The 
interaction between the presence of CVD and MetS was studied in relation to the 
presence or absence of T2DM in this population. 
 
METHODS 
Patients were selected from among those treated at the Integrated 
Center for Hypertension and Cardiovascular Metabolism of the Universidade 
Federal de São Paulo (UNIFESP, Federal University of São Paulo) with the 
following inclusion criteria: at least 18 years old, patients presenting at least one 
component of MetS and wash-out of one month from lipid modifying agents. The 
study protocol was approved by the UNIFESP Ethics in Research Committee. All 
individuals participating in the study gave written informed consent. The study was 
conducted in accordance with the Declaration of Helsinki and with Brazilian 
National Ministry of Health Resolution CNS 196/96. 
Patients presenting active infectious or inflammatory diseases were 
excluded, as were pregnant/breastfeeding patients and HIV-infected patients. The 
use of the following medications was discontinued in the four weeks preceding 
inclusion in the study: 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors 
(statins); cholesterol absorption inhibitors such as ezetimibe; probucol; 
cholestyramine; niacin; fibric acid derivates (fibrates); and drugs for treating 
obesity (orlistat and sibutramine). Temporary discontinuation of medications that 
alter the lipid profile was aimed at facilitating the appropriate characterization of 
MetS.  
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The patients were submitted to anamnesis and physical examination, 
in which weight, height, blood pressure (BP) and waist circumference were 
determined. Body mass index (BMI) was calculated by dividing weight in kilograms 
by height in meters squared (kg/m2). Blood pressure was obtained by a trained 
operator in the sitting position after five minutes of rest. A mercury 
sphygmomanometer was used according to a standard protocol and BP was 
calculated as the average after excluding the first of four measurements (25). 
For analysis of the metabolic profile, 30 mL of blood were collected 
from each participant after a 12-h fast. Fasting glycemia, serum levels of uric acid, 
total cholesterol and triglycerides were determined using an automated enzymatic-
colorimetric method. Fractions of HDL-cholesterol were measured using enzyme 
homogeneous colorimetric method and LDL-cholesterol was calculated using the 
Friedewald formula. The analyzer used was the Roche Hitachi 912 (Roche Hitachi, 
Montreal, Quebec). Serum levels of C-reactive protein (CRP) were determined 
using chemiluminescence immunoassay (Diagnostic Products Corporation, Los 
Angeles, CA, USA), with an analytical sensitivity of 0.01 mg/dL, intra-assay 
variability of 4.2-6.4% and inter-assay variability of 4.8-10%. 
The glomerular filtration rate (GFR) was estimated using the 
equations described in the MDRD study (26). The diagnosis of T2DM was made 
based on fasting glycemia and the need for treatment with hypoglycemic agents. 
Patient presenting angina were classified as having CVD, as were those with a 
confirmed history of acute myocardial infarction (MI), stroke, peripheral arterial 
obstruction or aortic aneurysm.  
The patients were classified according to a diagnosis of MetS, based 
on the NCEP and IDF criteria. The NCEP criteria define MetS as the presence of 
three or more of the following factors: elevated blood pressure ≥ 130/85 mmHg; 
waist circumference > 102 cm for men and > 88 cm for women; plasma 
triglycerides ≥ 150 mg/dL; HDL cholesterol < 40 mg/dL in men and < 50 mg/dL in 
women; and blood glucose ≥ 110 mg/dL. The guidelines proposed by the IDF 
identify waist circumference (≥ 94 cm for men and ≥ 80 cm for women) as an 
essential component for the diagnosis of MetS. Therefore, in order to meet the IDF 
criteria for MetS, an individual must present a large waist circumference, as well 
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as at least two of the following factors: elevated blood pressure ≥ 130/85 mmHg; 
plasma triglycerides ≥ 150mg/dL; HDL-cholesterol < 40 mg/dL in men and < 50 
mg/dL in women; and blood glucose ≥ 100 mg/dL. 
For those patients with primary prevention, cardiovascular risk was 
calculated using the Framingham score, which establishes the absolute 10-year 
risk of coronary artery disease (CAD) by sex. The risk factors employed are as 
follows: age; smoking; family history of CVD, HDL and systolic blood pressure. 
The score for each risk factor is calculated and associated with the absolute risk of 
CAD according to the percentage risk (low, medium or high).  
Data are expressed as means and standard deviations for variables 
with regular distribution and as medians for nonparametric variables. To test the 
differences found between patients with T2DM and those without diabetes in terms 
of the various variables analyzed, the Student’s t-test (for parametric variables) 
and the chi-square test (for nonparametric variables) were used. The groups were 
divided according to the presence or absence of T2DM, as well as to the presence 
or absence of MetS. The chi-square test was carried out with the aim of 
determining whether MetS correlated with CVD. Two models of binary logistic 
regression were employed, using CVD as a dependent variable. In one model, we 
included the following as independent variables: sex; age; creatinine clearance; 
serum levels of CRP; smoking; microalbuminuria; and a diagnosis of MetS 
according to NCEP criteria. In the second model, the independent variables 
included were as follows: sex; age; creatinine clearance, serum levels of CRP, 
smoking, microalbuminuria and a diagnosis of MetS according to IDF criteria. A 
receiver operating characteristic curve was constructed, and the area under the 
curve (AUC) was used in order to evaluate the value of a diagnosis of MetS, as 
defined using the NCEP criteria, the IDF criteria and the Framingham Score, in 
predicting a history of CVD. In all tests, the level of statistical significance required 
to reject the null hypothesis was set at 5% The statistical analysis was conducted 
using the Statistical Package for the Social Sciences, version 15.0 (SPSS, Inc., 
Chicago, IL, USA). 
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RESULTS 
The sample consisted of patients, but 26 of them were excluded 
because they did not fulfill the hypertension criteria. Females accounting for 66.8% 
(426 patients). The mean age was 57.7 ± 5.7 years and was similar for males and 
females. There were 202 patients with T2DM (31.7%). Of the 638 patients 
evaluated, 68 (10.7%) were smokers, and 64 (10.1%) had a history of CVD. Of the 
426 women in the sample, 334 (78.6%) were postmenopausal, and 12 (3.5%) of 
those were under hormone replacement therapy. In the sample as a whole, 262 
(41.1%) of the patients were overweight (BMI ≥ 25 kg/m2 and < 30 kg/m2) and 263 
(41.2%) were obese (BMI ≥ 30 kg/m2). (Table 1). There were 23.2% patients with 
low HDL (< 40 mg/dl in men and < 50 mg/dl in women) and 40.3% of the patients 
have elevated triglycerides.  
According to the criteria defined by the IDF, 349 (54.7%) of the 
patients presented MetS, compared with only 290 (45.5%) according to the NCEP 
criteria (p < 0.05). 
A diagnosis of MetS was associated with a greater than 20% 10-year 
risk of CAD, and this was true for the use of the NCEP criteria and the IDF criteria 
(OR: 5.98; 95% CI: 4.2-8.6 vs. OR: 5.84; 95% CI: 4.0-8.6, p < 0.05 for both). The 
use of the NCEP criteria to define MetS was found to have a sensitivity of 72.7% 
and a specificity of 69.1% for identifying patients with a greater than 20% 10-year 
risk of CAD. The use of the IDF criteria to define MetS was found to have a 
sensitivity of 80.3% and specificity of 58.8% for identifying such patients.  A 
diagnosis of MetS was associated with CVD using the NCEP criteria or the IDF 
criteria (OR: 2.04; 95% CI: 1.2-3.4 vs. OR: 2.68; 95% CI: 1.5-4.8, p < 0.05 for 
both.) We also observed that a high risk of CAD correlated significantly with a 
history of CVD (OR: 3.9; 95% CI: 2.3-6.7, p < 0.05).  
An NCEP or IDF criteria-based diagnosis of MetS was also 
associated with the development of T2DM (OR: 6.8; 95% CI: 4.7-10.0 vs. OR: 8.4; 
95% CI: 5.4-13.0, p < 0.05 for both). The table 2 discriminates the antihypertensive 
agents taken by the patients either with or without MetS (NCEP and IDF).  
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When the population was subdivided into patients with T2DM and 
those without diabetes, the correlation between the diagnoses of MetS, using 
either set of criteria, and a history of CVD began to differ. In the group without 
diabetes (Table 3), the association between an NCEP criteria-based diagnosis of 
MetS and a history of CVD ceased to exist (OR: 1.99; 95% CI: 0.9-4.3, p = NS). 
However, the correlation between an IDF criteria-based diagnosis of MetS and a 
history of CVD remained significant (OR: 2.4; 95% CI: 1.1-5.2; p = 0.029). The 
sensitivity and specificity of an IDF criteria-based diagnosis of MetS for identifying 
a history of CVD were 60.7% and 60.8%, respectively. 
The 202 patients with T2DM (Table 4) accounted for 31.7% of the 
sample, and 120 (59.4%) of those patients were female. Within this subgroup, 
already considered high risk, 16 (7.9%) were smokers and 39 (19.3%) had a 
history of CVD (OR: 3.7; 95% CI: 2.2-6.2, p < 0.05 vs. a history of CVD in patients 
without diabetes). The use of NCEP criteria in patients with T2DM resulted in a 
75.7% prevalence of MetS, compared with 85.1% when the IDF criteria were used. 
However, a diagnosis of MetS presented no association with a history of CVD, 
whether MetS was defined using the NCEP criteria (OR: 0.8; 95% CI: 0.4-1.7; p = 
0.54) or the IDF criteria (OR: 0.9; 95% CI: 0.4-2.5, p = 1.0).  
The logistic regression model included the presence of CVD as a 
dependent variable and the following as independent variables: sex; age; serum 
levels of uric acid; microalbuminuria; serum levels of CRP; smoking; creatinine 
clearance, as calculated using the modification of diet in renal disease method, 
and a diagnosis of MetS. Using this model, only an IDF criteria-based diagnosis of 
MetS and uric acid were found to be predictors of a history of CVD.  
When only non-classical cardiovascular risk factors 
(microalbuminuria, creatinine clearance, serum levels of uric acid and serum levels 
of CRP) were included as independent variables, a greater than 20% 10-year risk 
of CAD (as determined using the Framingham score) and serum levels of uric acid 
were shown to be predictors of a history of CVD. The AUC for the power of a 
diagnosis of MetS to predict a history of CVD was greater when the IDF criteria 
were used (AUC = 0.724; 95% CI: 0.66-0.789) than when the NCEP criteria were 
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used (AUC = 0.703; 95% CI: 0.634-0.776; p < 0.05) or when the Framingham 
score was used (AUC = 0,659; 95% CI; p < 0.05). 
The stratification of all patients due to the number of MetS 
components defined by both NCEP and IDF criteria was similar, and most patients 
presented two MetS components. 
We found that the number of MetS components, as defined using 
either criteria, correlated positively with the percentage of patients with CVD, as 
well as with serum levels of CRP. We found a greater proportion of patients with 
CVD and higher mean serum levels of CRP in those with more MetS components. 
 
 
DISCUSSION 
In the present study, we evaluated a final sample of 638 patients with 
hypertension and found the prevalence of MetS to be 45.5% when patients were 
analyzed according to NCEP criteria, compared with 54.7% when IDF criteria were 
applied. 
Our results show that the prevalence of MetS in this population with 
the inclusion of patients with essential hypertension, was similar to that reported 
by the American Heart Association Statistics Committee and Stroke Statistics 
Subcommittee (1), which found the prevalence of MetS, according to NCEP criteria, 
to be 43.5% in the American population between 60-69 years of age. In contrast, 
Ford et al. (27) evaluated 20,050 American noninstitutionalized individuals over the 
age of 20 in the Third National Health and Nutrition Examination Survey (NHANES 
III, conducted under the auspices of the National Centers for Disease Control and 
Prevention) and found the NCEP criteria-based prevalence of MetS to be 23.9%. 
The higher prevalence of MetS in our sample can be attributed to the inclusion of a 
greater number of older patients, as well as to the fact that our sample was 
composed of patients with at least one MetS component. 
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Comparing the two sets of criteria, the prevalence of MetS was 
higher when the IDF criteria were used than when the NCEP criteria were used. 
Our data are in accordance with the results of Lorenzo et al. (28), who 
demonstrated a higher prevalence of IDF criteria-based MetS than of NCEP 
criteria-based MetS. The author compared American individuals of two ethnicities 
(Hispanics and Caucasians), and, in both groups, more patients with MetS were 
identified when the IDF criteria were used. In addition, in a recent analysis 
involving 20,789 outpatient evaluations conducted as part of the NHANES 
between 1999 and 2002, Katzmarzyk et al. demonstrated that the prevalence of 
MetS according to IDF criteria was 50% greater that that determined using the 
NCEP criteria (29). 
Regardless of the criteria used, MetS contains variables which 
increase the risk of CVD (15,23). Despite this fact, not all studies associate MetS 
with a risk of CVD. The INTERHEART study (2) was a case-control study involving 
262 treatment facilities in 52 countries and evaluating the principal predictive 
factors of cardiovascular events. The study identified the variables responsible for 
95% of the risk of CVD, especially MI. In the subanalysis of that study, a diagnosis 
of MetS, as defined by NCEP criteria, was not predictive of CVD. In the present 
study, a diagnosis of MetS, regardless of the set of criteria used, was clearly 
associated with CVD. However, this association seemed to be at least partially 
dependent upon the inclusion of patients with T2DM. In fact, when patients with 
T2DM were excluded, the correlation between MetS and CVD remained significant 
only when the IDF criteria were used. It could be a result of high prevalence of 
MetS in patients with diabetes.  
Our results are in accordance with those of Lakka et al. and Eckel et 
al (4,30), who demonstrated a correlation between an NCEP criteria-based 
diagnosis of MetS and CVD, as well as with those of Nisson et al. (31), who showed 
that an IDF criteria-based diagnosis of MetS correlates with a significant increase 
in the occurrence of CVD. In fact, among individuals without diabetes, the mortality 
rate and incidence of CVD/CVA are two times and three times higher, respectively, 
for those with an IDF criteria-based diagnosis of MetS than for those without MetS. 
In addition, the risk of developing T2DM is five times greater for individuals with 
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MetS (19). It is possible that the elevated prevalence of CVD associated with MetS 
is due to insulin resistance (32), which is associated with endothelial dysfunction 
and the atherosclerosis process. 
Due to a strong association between larger waist circumference and 
insulin resistance, the IDF definition of MetS includes, as an obligatory criterion, a 
larger waist circumference, with cut-off values determined by gender and 
ethnicity (33). On the basis of epidemiological data, the waist circumference cut-off 
point has been reduced for various ethnic groups (34-38). Tan et al. (39) studied 4723 
individuals of different ethnicities in Singapore and observed that when MetS was 
defined using lower values of waist circumference (< 80 cm in women and < 90 cm 
in men, values similar to those proposed by the IDF), it was possible to identify 
patients at risk for CVD with greater reliability than when NCEP values were used. 
In this context, the characterization of waist circumference by ethnic group has its 
relevance, since the definition established by the NCEP criteria, when applied to 
Asian and European populations might underestimate the prevalence of MetS and, 
consequently, fail to identify individuals with risk of CVD. Tan et al. did not 
evaluate the risk of CVD in the population of patients with and without diabetes. 
The impact that a diagnosis of MetS has on the incidence of CVD in 
patients with diabetes is not well established yet. Haffner et al. showed that the 
presence of T2DM increases the risk of CAD, making it similar to that of 
individuals without diabetes who have already suffered a coronary event (40). The 
authors found that the incidence of MI in individuals with T2DM and no history of 
CVD was similar to that of those without diabetes and with a history of MI. 
Therefore, they dubbed T2DM a CAD risk 'equivalent'. The Framingham study had 
already called the attention to the fact that T2DM doubles the risk of CVD in men 
and triples it in women. In a recent evaluation of MetS sponsored by the American 
Association of Diabetes and the European Association for the Study of Diabetes, 
Bruno et al. (41) found that, in patients with diabetes, a diagnosis of MetS has little 
or no value in determining CVD mortality risk (42). The study involved 1565 patients 
with diabetes in outpatient treatment for 8 years. The authors found the prevalence 
of MetS to be 76%, and the relative risk for all-cause mortality, as well as for 
cardiovascular mortality, in the group with MetS was similar to that of patients with 
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T2DM without MetS. Similarly, Lorenzo et al. showed that MetS was not predictive 
of CVD in patients with a history of CVD or equivalent ischemic vascular 
events (43). In addition, a retrospective analysis conducted by Carole et al., 
involving data from the United Kingdom Prospective Diabetes Study, provided a 
better evaluation of the association between MetS and CVD in patients with 
diabetes through the simultaneous analysis of different definitions of MetS in a 
more than 50,000 person-years of follow-up evaluation. In that analysis, there was 
a considerable superimposition in the estimate of risk of CVD in 10 years between 
T2DM patients with and without MetS, and the authors attributed limited clinical 
value to the diagnosis of MetS for the stratification of cardiovascular risk in 
patients with T2DM. Our data are in accordance with those cited, since we did not 
find a correlation between MetS and CVD when we evaluated patients with T2DM, 
regardless of the criteria used to define MetS. However, in patients without 
diabetes, a diagnosis of MetS based solely on the IDF criteria was associated with 
a higher frequency of CVD. 
In summary, we can affirm that the prevalence of MetS, at least in 
patients without diabetes, depends on the criteria applied. In the patients without 
diabetes, MetS defined by IDF criteria alone was associated with a higher 
frequency of CVD. In patients with T2DM, a diagnosis of MetS, regardless of the 
criteria adopted, was not associated with CVD. A diagnosis of MetS, regardless of 
the diagnostic criteria applied, showed a strong association with the occurrence of 
T2DM. 
We conclude that, in patients without diabetes, a diagnosis of MetS 
according to IDF criteria is useful in identifying individuals with a higher probability 
of presenting CVD. In patients with diabetes, a population already considered at 
high risk for CVD, a diagnosis of MetS, regardless of the criteria used, has no 
impact on prognosis. Nevertheless, in patients without diabetes, a diagnosis of 
MetS, regardless of the criteria used, can identify individuals more likely to develop 
T2DM.   
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Table 1: Demographic characteristics and biochemical evaluation of patients with and 
without metabolic syndrome according to the two sets of criteria.  
 Diagnosis of MetS using NCEP 
criteria 
 Diagnosis of MetS using IDF 
criteria 
 Yes No p*  Yes No p* 
 n (%) n (%)   n (%) n (%)  
n 290 (45%) 348 (55%)    349 (54.7%) 289 (45.3%)   
Female, n (%) 205 (70.7)   ns  242 (96.3%)   ns 
Age (years) 57.9 ± 9.5 57.6 ± 10.5 ns  57.9 ± 9.5 57.6 ± 11.0 ns 
BMI (kg/m2) 32.1 ± 4.7 27.5 ± 4.6 <0.05  31.4 ± 4.9 27.5 ± 4.7 <0.05 
SBP (mmHg) 139 ± 19 136 ± 20 <0.05  138 ± 19 136 ± 21 ns 
DBP (mmHg) 86 ± 11 84 ± 11 ns  86 ± 11 85 ± 11 ns 
Waist circumference (cm) men 105.8 ± 10 94.1 ± 8.5 <0.05  105.1 ± 8.4 92.3 ± 9.1 <0.05 
Waist circumference (cm)women 101.3 ±10 90.0 ±12 <0.05  99.3±11 90.9±12 <0.05 
TC (mg/dL) 213.5 ± 45 209.2 ± 37 ns  213.2 ± 44 209.2 ± 37 ns 
HDL-C (mg/dL) 50.8 ± 13 61.9 ± 15 <0.05  52.3 ± 13 62 ± 16 <0.05 
LDL-C (mg/dL) 123.9 ± 38 123.2 ± 33 ns  124.5 ± 37 122.4 ± 34 ns 
TG (mg/dL) 197.8 ± 111 120.5 ± 62 <0.05  186.7 ± 107 118.2 ± 61 <0.05 
Blood glucose (mg/dL)  117.8 ± 49 93.1 ± 34 <0.05  115.1 ± 46 91.3 ± 37 <0.05 
Uric acid (mg/dL) 6.0 ± 1.6 5.2 ± 1.6 <0.05  5.9 ± 1.6 5.3 ± 1.6 <0.05 
Creatinine (mg/dL) 1.0 ± 0.3 1.0 ± 0.2 ns  1.0 ± 0.2 1.0 ± 0.2 ns 
Creatinine clearance (ml/min/1.73m2) 68.8 ± 15 71.5 ± 12.8 <0.05  69.5 ± 14 71.2 ± 13 ns 
Potassium (mEq/L) 4.4 ± 0.4 4.5 ± 0.5 ns  4.4 ± 0.4 4.5 ± 0.5 ns 
Microalbuminuria (µg/min) 62.8 ± 233 18.6 ± 118 <0.05  45.6 ± 175 30.2 ± 187 ns 
CRP (mg/dL) 0.7 ± 0.8 0.5 ± 0.6 <0.05  0.7 ± 0.7 0.5 ± 0.6 <0.05 
Framingham score 15 ± 3.7 13 ± 4.3 <0.05  14.7 ± 3.7 13.1 ± 4.5 <0.05 
MetS: metabolic syndrome; NCEP: National Cholesterol Education Program; IDF: International Diabetes Federation; ns: not 
significant; BMI: body mass index; SBP: systolic blood pressure; DBP: diastolic blood pressure; TC: total cholesterol; HDL-
C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol; TG: triglycerides; CRP: C-reactive protein. 
*vs. patients without MetS. 
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Table 2: discriminates the stratification of MetS components as well as the 
antihypertensive agents taken by the patients either with or without MetS (NCEP and IDF) 
 TOTAL  NCEP  IDF 
  N %  N %  N % 
DIURETICS 350 54,9  179 61,7  266 76,2 
ACEi/ARB 414 64,9  221 76,2  211 60,5 
CCB AGENTS 179 28,1  89 30,7  103 29,5 
BETA BLOCKING AGENTS 118 18,5  52 17,9  66 18,9 
OUTROS 27 4,2  15 5,1  16 4,6 
ACEi: Angiotensina-Conveting Enzime inhibitor; ARB: Angiotensin II Receptor blocking; CCB: calcium channel blocking. 
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Table 3: Demographic characteristics and biochemical evaluation of patients without 
diabetes (with and without metabolic syndrome according to the two sets of criteria).  
 Diagnosis of MetS using NCEP 
criteria 
 Diagnosis of MetS using IDF 
criteria 
 Yes No p*  Yes No p* 
 n (%) n (%)   n (%) n (%)  
n 137 (31.4%) 298 (68.3%)    177 (40.6%) 285 (59.2%)   
Female, n (%) 104 (75.9%)   ns  129 (72.9%)   ns 
Age (years) 56.1 ± 9.4 57.2 ± 10.8 ns  56.3 ± 9.3 57.2 ± 11.0 ns 
BMI (kg/m2) 32.2 ± 5.0 27.8 ± 4.7 <0.05  31.3 ± 5.2 27.7 ± 4.7 <0.05 
SBP (mmHg) 139 ± 19 137 ± 20 ns  138 ± 19 137 ± 20 ns 
DBP (mmHg) 88 ± 11 85 ± 11 <0.05  87 ± 11 85 ± 11 <0.05 
Waist circumference (cm) men 104.3±9 94.6 ± 9 <0.05  103.5 ± 6.1 93.3 ±9.8 <0.05 
Waist circumference (cm) women 101.3±10.6 90.45±11.8 <0.05  99.1±11.4 90.5±12 <0.05 
TC (mg/dL) 218.9 ± 42 211.3 ± 36 ns  218.5 ± 41 210.4 ± 36 <0.05 
HDL-C (mg/dL) 48.1 ± 10 62.2 ± 15 <0.05  50.2 ± 11 63.0 ± 15 <0.05 
LDL-C (mg/dL) 130.6 ± 37 124.6 ± 33 ns  130.4 ± 36 124.0 ± 33 ns 
TG (mg/dL) 204.4 ± 85 122.3 ± 59 <0.05  195.44 ± 85 115.8 ± 53 <0.05 
Blood glucose (mg/dL)  88.8 ± 12 84.2 ± 10 <0.05  89.5 ± 12 83 ± 9 <0.05 
Uric acid (mg/dL) 6.1 ± 1.5 5.3 ± 1.5 <0.05  6.0 ± 1.5 5.2 ± 1.5 <0.05 
Creatinine (mg/dL) 1.0 ± 0.2 1.0 ± 0.2 ns  1.0 ± 0.2 1.0 ± 0.2 ns 
Creatinine clearance (ml/min/1.73m2) 69.7 ± 14 71.1 ± 13 ns  70.1 ± 13 71± 13 ns 
Potassium (mEq/L) 4.4 ± 0.4 4.5 ± 0.5 ns  4.4 ± 0.4 4.5 ± 0.5 <0.05 
Microalbuminuria (µg/min) 29.8 ± 107 12.7 ± 57 <0.05  25.1 ± 95 13.7 ± 60 ns 
CRP (mg/dL) 0.7 ± 0.7 0.5 ± 0.6 <0.05  0.7 ± 0.7 0.5 ± 0.6 <0.05 
Framingham score 15 ± 3.7 13 ± 4.5 <0.05  14.7 ± 3.7 13.2 ± 4.6 <0.05 
MetS: metabolic syndrome; NCEP: National Cholesterol Education Program; IDF: International Diabetes Federation; ns: not 
significant; BMI: body mass index; SBP: systolic blood pressure; DBP: diastolic blood pressure; TC: total cholesterol; HDL-
C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol; TG: triglycerides; CRP: C-reactive protein. 
*vs. patients without MetS. 
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Table 4: Demographic characteristics and biochemical evaluation of patients with 
diabetes (with and without metabolic syndrome according to the two sets of criteria).  
 Diagnosis of MetS using NCEP 
criteria 
 Diagnosis of MetS using IDF 
criteria 
 Yes No p*  Yes No p* 
 n (%) n (%)   n (%) n (%)  
n 153 (75.7%) 49 (24.3%)   172 (85.1%) 30 (14.9%)  
Female, n (%) 113 (65.7%)  <0.05  101 (66%)  <0.05 
Age (years) 59.5 ± 9.4 60.5 ± 8.5 ns  57.5 ± 9.3 60.8 ± 8.5 ns 
BMI (kg/m2) 32.0 ± 4.5 26.2 ± 3.7 <0.05  31.5 ± 4.6 25.7 ± 4.6 <0.05 
SBP (mmHg) 139 ± 18 127 ± 17 <0.05  138 ± 18 124.7 ± 17 <0.05 
DBP (mmHg) 85 ± 11 79.7 ± 8 <0.05  84 ± 11 80 ± 9 ns 
Waist circumference (cm) men 106.6 ± 11 92.6 ±6.4 <0.05  106.4 ± 9.7 88.8 ± 5 <0.05 
Waist circumference (cm) women 101.3±9.5 85.4±13.3 <0.05  99.5±10.5 87.9±22.5 <0.05 
TC (mg/dL) 208.6 ± 48 196.2 ± 41 ns  207.7 ± 47 193.9 ± 45 ns 
HDL-C (mg/dL) 53.1 ± 15 59.6 ± 17 <0.05  54.5 ± 15 55.9 ± 20 ns 
LDL-C (mg/dL) 117.8 ± 38 114.8 ± 35 ns  118.3 ± 37 110.1 ± 38 ns 
TG (mg/dL) 192.0 ± 130 109.57 ± 73 <0.05  177.6 ± 126 139.8 ± 106 ns 
Blood glucose (mg/dL)  143.8 ± 55 147.5 ± 66 ns  141.5 ± 52 163.0 ± 82 ns 
Uric acid (mg/dL) 6.0 ± 1.7 5.2 ± .21 <0.05  5.8 ± 1.7 5.7 ± 2.5 ns 
Creatinine (mg/dL) 1.1 ± 0.3 1.0 ± 0.2 ns  1.0 ± 0.3 1.1 ± 0.3 ns 
Creatinine clearance (ml/min/1.73m2) 68 ± 16 74.4 ± 14 <0.05  69.9 ± 15 73.3 ± 16 ns 
Potassium (mEq/L) 4.4 ± 0.5 4.6 ± 0.5 ns  4.5 ± 0.5 4.6 ± 0.6 ns 
Microalbuminuria (µg/min) 92.7 ± 303 53.2 ± 276 ns  66.7 ± 228 176.5 ± 542 ns 
CRP (mg/dL) 0.7 ± 0.8 0.4 ± 0.6 <0.05  0.7 ± 0.7 0.5 ± 0.7 ns 
Framingham score 14.8 ± 3.7 13 ± 3.2 <0.05  14.6 ± 3.7 12.9 ± 3.0 <0.05 
MetS: metabolic syndrome; NCEP: National Cholesterol Education Program; IDF: International Diabetes Federation; ns: not 
significant; BMI: body mass index; SBP: systolic blood pressure; DBP: diastolic blood pressure; TC: total cholesterol; HDL-
C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol; TG: triglycerides; CRP: C-reactive protein. 
*vs. patients without MetS. 
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FIGURE LEGENDS 
Figure 1: Receiver operating characteristic (ROC) curve: cardiovascular disease in 
relation to the Framingham Score, as well as to metabolic syndrome according to the 
National Cholesterol Education Program (NCEP) and International Diabetes Federation 
(IDF) criteria, in the population studied 
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ANEXOS 
ANEXO 1: Termo de consentimento livre e esclarecido 
 
 
Hospital do Rim e Hipertensão 
Disciplina de Nefrologia 
Universidade Federal de São Paulo – UNIFESP 
 
Polimorfismo de Genes de Citocinas: Impacto nas Subfrações de Lipoproteínas em 
Hipertensos Estratificados de Acordo com os Componente da Síndrome Metabólica 
 
TERMO DE CONSENTIMENTO 
 
Proposta do estudo: Eu entendo que está sendo solicitada a minha participação, como 
voluntário(a), em uma Pesquisa que irá estudar o polimorfismo (estudo genético) das citocinas 
(grupos moleculares responsáveis pela resposta inflamatória do corpo humano) e o perfil das 
lipoproteínas (lipídeos do sangue) em pacientes portadores de hipertensão arterial, comparando-os a 
um grupo de indivíduos sem doença. 
Importância do estudo: Pacientes com hipertensão arterial têm maior risco de doença coronariana 
que indivíduos sem doença. Dados de pesquisas anteriores já demonstram estreita relação entre a 
ateosclerose, a dislipidemia e os processos inflamatórios crônicos. Estudos mais recentes 
demonstram que também na hipertensão arterial a resposta inflamatória está envolvida na 
ocorrência de doenças cardiovasculares (infarto, angina e acidentes vasculares cerebrais). A análise 
genética, através do estudo do polimorfismo das citocinas, tem proporcionado grande avanço no 
entendimento das doenças cardiovasculares. De maneira semelhante, a hipertensão arterial 
ocasiona alteração do perfil lipídico, com aumento do nível de triglicérides e redução dos níveis de 
HDL, o que facilita a ocorrência de doença coronariana. Este Estudo proporcionará melhor avaliação 
deste fatores de risco (redução do HDL e aumento do triglicérides) em pacientes com hipertensão 
arterial analisados sob a ótica da inflamação. 
População do estudo: Eu entendo que, para participar deste Estudo, devo ter idade maior que 18 
anos e devo preencher os critérios científicos estabelecidos pelos pesquisadores. Eu não poderei 
participar do estudo se estiver recebendo qualquer medicação para tratar dislipidemia. 
Procedimento: Será solicitada a minha presença no Ambulatório de Hipertensão da Disciplina de 
Nefrologia da Universidade Federal de São Paulo para que eu seja submetido(a) a coleta de 40 ml 
de sangue para a mensuração de perfil lipídico e estudo dos genes envolvidos na inflamação 
(citocinas). Entendo que parte da amostra de sangue coletada poderá ser utilizada em futuros 
estudos de genes envolvidos na inflamação e doença cardiovascular. Eu entendo que, ao me 
apresentar para a coleta de sangue, deverei estar em jejum (incluindo qualquer tipo de líquido) nas 
12 horas precedentes. 
Risco do procedimento: Eu entendo que não há maior risco ou perigo relacionado à minha 
participação no estudo. Também entendo que a coleta de sangue poderá ocasionar pequeno 
desconforto no local da punção bem como eventual formação de hematoma. 
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Benefícios: Eu entendo que não haverá benefício direto, nem compensação financeira, 
relacionados à minha participação neste Estudo. No entanto, esta pesquisa poderá proporcionar 
novas e relevantes informações dos fatores de risco para doença coronariana relacionados à 
inflamação e à hipertensão arterial. Eu entendo que posso desistir de participar deste Estudo quando 
for da minha vontade sem que isso afete qualquer tratamento médico futuro nesta Instituição. 
Confidencialidade: Eu entendo que toda informação produzida por este Estudo será confidencial e 
privada. Se esta informação for utilizada para publicação em literatura médica ou com finalidade de 
ensino, não será fornecida a identidade dos participantes. Os arquivos derivados deste Estudo serão 
mantidos confidenciais e só serão liberados por força da lei. 
Eu fui orientado(a), em caso de qualquer dúvida, procurar o seguinte pesquisador: 
Dra. Andréa Harumi Hirota 
 
Eu li este Termo de consentimento e discuti as minhas dúvidas com a Dra. Andréa Harumi Hirota ou 
seu(ua) representante a respeito dos procedimentos do Estudo. Eu tive a oportunidade de fazer 
perguntas, que foram respondidas satisfatoriamente. 
Eu fui completamente informado sobre o Estudo acima descrito e sobre os seus potenciais riscos e 
benefícios, e consinto com a realização dos procedimentos necessários a realização do referido 
Estudo. 
 
 
Data: ____/_____/_____  _______________________________________ 
     Participante 
 
Data: ____/_____/_____  _______________________________________ 
     Investigador 
 
Data: ____/_____/_____  _______________________________________ 
     Testemunha 
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Anexo 2: Aprovação pelo comitê de ética médica. 
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